Convergence born with a pain relief therapy pipeline UK pharma company GlaxoSmithKline has spunout a new biotech company, Convergence Pharmaceuticals, with former staff and patents from its investigational pain relief drug pipeline. GSK retains an 18% stake in Convergence Pharmaceuticals after ...

The FDA has warned that the GlaxoSmithKline's drug Lamictal (lamotrigine), approved to treat seizures and bipolar disorder, can cause aseptic meningitis, an inflammation of the protective membranes (meninges) that cover the brain and spinal cord not caused by bacterial ...

GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously agreed that the drug would benefit epilepsy patients...

GlaxoSmithKline is paying UK-based Vectura group $31.8 million dollars to license Vectura's dry powder drug formulation patents in relation to two late stage development compounds in GSK's respiratory drug pipeline. The drugmaker gets will receive up t...

GlaxoSmithKline (NYSE: GSK) has obtained an exclusive licence to develop and commercialize an antibiotic derived from Anacor's boron chemistry platform. As a result, Anacor will receive $15 million and is eligible for further milestone paymen...

GlaxoSmithKline (NYSE: GSK) and partner Shionogi would be progressing the experimental medicine S/GSK1349572, into Phase III clinical trials later this year, following promising results from two Phase IIb studies. S/GSK1349572 belongs to a class of anti-AIDS agents as integrase inhibitor. According ...

The U.K.'s biggest drug company GlaxoSmithKline Plc has confirmed that they agree to pay more than $1 billion to resolve more than 800 cases alleging its antidepressant medicine Paxil caused birth defects in some users’ children. “The company has agreed to ...

There's quite a competition these days for the best minds in the field of adaptive immune responses, and GlaxoSmithKline has provided Tempero Pharmaceuticals with some of the hottest recruits to be found in this emerging class of new drugs. As Xconomy'...

GlaxoSmithKline Plc’s fight to win the backing of a U.S. advisory panel to keep its diabetes pill Avandia on the market suggests drugmakers are facing stricter scrutiny for their products from regulators, analysts said. A Food and Drug Administration advisory ...

GlaxoSmithKline Plc agreed to pay about $460 million to resolve a majority of lawsuits alleging the company’s Avandia diabetes drug can cause heart attacks and strokes, people familiar with the accords said. Glaxo, the U.K.’s biggest drugmaker, agreed to settle ...